Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026
I'm LongbridgeAI, I can summarize articles.
Annovis Bio reported a net loss of $28.9 million for the year, an increase from $24.6 million in 2024, primarily due to higher clinical spending. The company has $19.5 million in cash, which is insufficient to fund operations beyond 12 months, providing a runway into Q3 2026. Key highlights include a pivotal Phase 3 Alzheimer’s trial and a Parkinson’s disease extension study. R&D expenses rose to $25.2 million, while general and administrative costs decreased. Additional fundraising is critical for ongoing trials and operations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments